---
title: Semaglutide and Cognition in Healthy Volunteers
nct_id: NCT06363487
overall_status: COMPLETED
phase: NA
sponsor: University of Oxford
study_type: INTERVENTIONAL
primary_condition: Cognitive Change
countries: United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06363487.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06363487"
ct_last_update_post_date: 2025-06-06
last_seen_at: "2026-05-12T07:26:14.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Semaglutide and Cognition in Healthy Volunteers

**Official Title:** Effects of Single-dose Semaglutide on Cognition and Energy in Healthy Volunteers

**NCT ID:** [NCT06363487](https://clinicaltrials.gov/study/NCT06363487)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 70
- **Lead Sponsor:** University of Oxford
- **Collaborators:** National Institute for Health Research, United Kingdom
- **Conditions:** Cognitive Change
- **Start Date:** 2024-06-06
- **Completion Date:** 2024-12-11
- **CT.gov Last Update:** 2025-06-06

## Brief Summary

Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA). It is a safe medication approved for use in type-2 diabetes mellitus (T2DM) and obesity. Primarily, it works by counteracting insulin-resistance and inducing weight loss. It also acts on several other interconnected neurobiological, immunological (esp. inflammatory), endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms. Its effects on cognition and energy are currently unknown. In this study we are using semaglutide as an experimental tool to further investigate these relationships.

## Detailed Description

Semaglutide is a novel GLP-1RA licensed for T2DM and obesity, which mainly works by offsetting insulin-resistance and stimulating weight loss (1). It also acts on various neurobiological, immunological, endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms (2). Preliminary evidence suggests these drugs are safe from a neuropsychiatric perspective (3) and could be beneficial in unipolar (4) and bipolar depression (5) - an outcome possibly mediated by inflammatory pathways (6).

The proposed study investigates the effects of semaglutide on cognition and energy, which are currently unknown. Work in our laboratory established that short-term use of conventional antidepressants in healthy volunteers shifts reward sensitivity and emotional cognition (7) - an important neuropsychological mechanism of antidepressant action (8). An experimental medicine trial that assesses the effects of semaglutide on reward sensitivity emotional cognition can validate its potential to be repurposed for treating depressive disorders (9). Moreover, brain insulin resistance, likely lessened by semaglutide, is associated with deficit in impulse-control as well as non-emotional cognitive and energy impairment in people with depression (10). Finally, defining the overall cognitive and energy profile of semaglutide is important for the many people already taking it for its licensed indications (i.e., T2DM, obesity).

Therefore, the primary objective of this study is to assess the effect of a single dose of semaglutide 0.5mg subcutaneous injection vs placebo on reward sensitivity tasks in healthy volunteers. Secondary objectives include the investigation of the effects of semaglutide on other cognitive domains (emotional processing, impulsivity, memory) and energy/activity levels. Psychological questionnaires are also measured as relevant covariates.

## Eligibility

- **Minimum age:** 21 Years
- **Maximum age:** 55 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Male or female
* Aged from 21 to 55 years
* Body Mass Index (BMI) from 18 to 30 (because our main outcomes involve cognitive and energy measures, this decision regarding the BMI range has been taken with the purpose of including a more homogeneous sample of healthy participants in terms of baseline cognitive and energy levels)
* Sufficiently fluent English to understand and complete the tasks
* Participant is willing and able to give informed consent for participation in the research
* Not currently taking any regular medications (except the contraceptive pill)

Exclusion Criteria:

* Currently on any regular prescribed medications (except the contraceptive pill), unless unlikely to compromise safety or affect data quality in the opinion of the medical supervisor according to clinical judgement
* History of, or current significant psychiatric illness in the opinion of the medical supervisor according to clinical judgement
* Current alcohol or substance misuse disorder (\<6 months)
* Current moderate or severe dyslexia
* History of, or current significant medical illness in the opinion of the medical supervisor according to clinical judgement
* History of, or current pancreatitis
* History of, or current severe congestive heart failure, end-stage renal disease, hepatic disease
* History of, or current significant neurological condition (e.g., epilepsy)
* History of, or current significant thyroid disorder
* History (including family history) of, or current multiple endocrine neoplasia syndrome type-2 (MEN 2) or medullary thyroid carcinoma (MTC)
* Known type-1 or type-2 diabetes mellitus
* Known hypersensitivity to the study drug (i.e., semaglutide)
* Pregnant, breast feeding, or person of child-bearing potential not using appropriate contraceptive measures including hormonal contraception, intrauterine device, bilateral tubal occlusion, vasectomised partner, condom, absolute sexual abstinence - periodic sexual abstinence, withdrawal, and spermicides-only are not acceptable methods of contraception
* Participation in a study that uses the same or similar computer tasks (O-ETB, see below) as those used in the present study
* Participation in a study that involves the use of a medication within the last 3 months
```

## Arms

- **Semaglutide** (EXPERIMENTAL) — Semaglutide pre-filled pen, 0.5mg in 1.5mL, subcutaneous injection
- **Placebo** (PLACEBO_COMPARATOR) — Saline solution 0.9% NaCl, solution for injection 1.5mL, subcutaneous injection syringe

## Interventions

- **Semaglutide, 0.5 mg/mL** (DRUG) — Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
- **Placebo, 0.9% NaCl 1.5mL** (OTHER) — Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.

## Primary Outcomes

- **Reward (learning)** _(time frame: 6-7 days)_ — Win/loss and valence on a computer-based task of reward processing (i.e., probabilistic instrumental learning task), comparing those receiving drug vs placebo.
- **Reward (effort-based)** _(time frame: 6-7 days)_ — Win/loss and valence on a computer-based task of reward processing (i.e., apple-gathering task), comparing those receiving drug vs placebo.
- **Reward (primary)** _(time frame: 6-7 days)_ — Valence on a computer-based task of reward processing (i.e., taste strip task), comparing those receiving drug vs placebo.

## Secondary Outcomes

- **Emotional processing** _(time frame: 6-7 days)_
- **Emotional impulsivity** _(time frame: 6-7 days)_
- **Memory (short- and medium-term) processing** _(time frame: 6-7 days)_
- **Memory (working) processing** _(time frame: 6-7 days)_
- **Energy/activity** _(time frame: Across 6-7 days)_

## Locations (1)

- Department of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.department of psychiatry, university of oxford|oxford|oxfordshire|united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06363487.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06363487*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*